Status:

COMPLETED

Erythroferrone and Its Impact on Maternal and Neonatal Iron Homeostasis

Lead Sponsor:

Cornell University

Collaborating Sponsors:

University of California, Los Angeles

Conditions:

Pregnancy Anemia

Newborn; Anemia

Eligibility:

FEMALE

11-45 years

Brief Summary

Erythroferrone (ERFE) is a recently identified iron-regulatory hormone that couples iron homeostasis to erythropoiesis but at this time there are no human data on this hormone in pregnant women and th...

Eligibility Criteria

Inclusion

  • Healthy pregnant volunteers

Exclusion

  • Hemoglobinopathies
  • Pre-existing diabetes
  • Malabsorption diseases
  • Pregnancy induced hypertension
  • Elevated diastolic blood pressure (\>110)
  • Previous treatment for lead exposure or elevated childhood lead concentrations.
  • Preexisting medical conditions known to impact iron homeostasis

Key Trial Info

Start Date :

April 1 2006

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2017

Estimated Enrollment :

338 Patients enrolled

Trial Details

Trial ID

NCT04517734

Start Date

April 1 2006

End Date

December 1 2017

Last Update

March 22 2022

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Rochester Adolescent Maternity Program

Rochester, New York, United States, 14609

2

Strong Memorial Hospital

Rochester, New York, United States, 14620

Erythroferrone and Its Impact on Maternal and Neonatal Iron Homeostasis | DecenTrialz